Detalhe da pesquisa
1.
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
BMC Cancer
; 23(1): 708, 2023 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507657
2.
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
N Engl J Med
; 378(22): 2078-2092, 2018 May 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29658856
3.
Emerging biomarkers for immune checkpoint inhibition in lung cancer.
Semin Cancer Biol
; 52(Pt 2): 269-277, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782924
4.
Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Cancer
; 124(10): 2174-2183, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29533458
5.
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours.
Br J Cancer
; 119(12): 1471-1476, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30425349
6.
Pembrolizumab for the treatment of non-small-cell lung cancer.
N Engl J Med
; 372(21): 2018-28, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891174
7.
Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer.
Proc Natl Acad Sci U S A
; 112(5): 1547-52, 2015 Feb 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-25605928
8.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol
; 17(11): 1497-1508, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27745820
9.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Lancet Oncol
; 17(2): 234-242, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26708155
10.
Pembrolizumab plus Chemotherapy in Lung Cancer.
N Engl J Med
; 379(11): e18, 2018 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30207917
11.
A phase 1 study of ABT-806 in subjects with advanced solid tumors.
Invest New Drugs
; 33(3): 671-8, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25895099
12.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
; 15(10): 1119-28, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25153538
13.
Identifying Oncology Clinical Trial Candidates Using Artificial Intelligence Predictions of Treatment Change: A Pilot Implementation Study.
JCO Precis Oncol
; 8: e2300507, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513166
14.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
N Engl J Med
; 363(18): 1693-703, 2010 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-20979469
15.
Small cell lung cancer.
J Natl Compr Canc Netw
; 11(1): 78-98, 2013 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23307984
16.
Immunotherapy in patients who have NSCLC without EGFR or ALK mutations.
Clin Adv Hematol Oncol
; 16(7): 484-485, 2018 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-30067619
17.
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
Lancet Oncol
; 13(10): 1011-9, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22954507
18.
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer.
J Immunother
; 44(7): 264-275, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33928928
19.
Safety and activity of the TGFß receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
J Immunother Cancer
; 9(3)2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33688022
20.
Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2).
J Thorac Oncol
; 16(2): 327-333, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33166722